Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Temporarily not available 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 2Expanded_access 1

Sponsor

Cancer Type

Lymphoid 1Genitourinary 1

Conditions

Recurrence 1Kidney Neoplasms 1KRAS G12V Mutant Advanced Epithelial Cancers 1Hodgkin Disease 1

Interventions

Cisplatin 3193Cyclophosphamide 3187Carboplatin 2968Radiotherapy 2784Paclitaxel 2716Gemcitabine 2569pembrolizumab 2378Bevacizumab 2206Docetaxel 2196Fluorouracil 1848Capecitabine 1828Oxaliplatin 1738Dexamethasone 1604Nivolumab 1580Doxorubicin 1501Rituximab 1487Magnetic Resonance Spectroscopy 1382Etoposide 1345Irinotecan 1245Leucovorin 1222Drug Therapy 1202Cytarabine 1130Pemetrexed 1074fludarabine 1056Specimen Handling 1009Vincristine 964Cetuximab 943Prednisone 940Trastuzumab 940Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Insulin Infusion Systems × Clear all
NCT03354390 2026-04-28

HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma

National Institutes of Health Clinical Center (CC)

Phase 1 Active not recruiting
17 enrolled 15 charts
Genitourinary

Kidney Neoplasms

NCT05389514 2025-11-20

Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors

Providence Health & Services

Temporarily not available

KRAS G12V Mutant Advanced Epithelial Cancers

NCT06090864 2025-10-20

ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Recruiting
31 enrolled
Lymphoid

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡